Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile ...

Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile fill-finish and packaging facility in Ridgefield, N.J. The science-services and instruments provider said Wednesday that it ...

Thermo Fisher Scientific Inc. has expanded its strategic partnership with Sanofi to enable additional U.S. drug product manufacturing.

Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical ...

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

By Denny Jacob American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi ...

Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024.

Sanofi SA has selected KT-485 (SAR-447971) to advance into clinical studies under its IRAK-4 partnership with Kymera Therapeutics Inc. KT-485 is a first-in-class, selective, potent, oral IRAK-4 ...